The Max Foundation, a global nonprofit organization that aims to accelerate health equity by delivering medication, technology, and supportive services to patients globally, will launch access to the Novartis therapy Scemblix (asciminib) in 36 low- and middle-income countries in 2023 for people living with chronic myeloid leukemia as part of the CancerPath to Care collaboration with Novartis.
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe